Y-mAbs’ External Control Problems May Sink Neuroblastoma Candidate I-Omburtamab
Executive Summary
In advisory committee briefing documents, the US FDA said control data was not comparable to the single-arm trial and the benefits of the monoclonal antibody were unclear.